Pradaxa

Pradaxa (chemical name dabigatran), is manufactured by the privately held German company Boehringer Ingelheim and was approved for use in the United States in October, 2010. Pradaxa is used in patients with atrial fibrillation (dangerous irregular heartbeat) as an anticoagulant medicine that reduces the risk of blood clots forming in the body and causing a stroke. Atrial fibrillation mostly affects the elderly. Pradaxa is a direct thrombin inhibitor meant to replace warfarin. One of the main problems with Pradaxa is in the event of traumatic hemorrhage, there are currently no effective reversal agents. The Journal of Neurosurgery cites the case of an 83 year old man that was hospitalized following a routine fall. Initial CT scans revealed small, superficial area of hemorrhage in his brain. A repeat CT scan two hours later showed a massive brain hemorrhage that resulted in the patient’s death.

If you or someone you know has suffered as a result of Pradaxa, contact Law Offices of Gary Green toll free at 1-888-4GARYGREEN or send us an e-mail at ggreen@gGreen.com

Print Friendly